Advancing a New Class of Medicines

Company to Watch – NeuBase Therapeutics In the second of four features on NeuBase Therapeutics, Big4Bio spoke with Founder and CEO Dietrich Stephan and CFO Todd Branning about the company’s precision genetic medicine technology and pipeline, partnering and financing activities, and plans moving forward. By Marie Daghlian Todd Branning, chief financial officer of NeuBase Therapeutics, […]

Read More

The Big4Bio Company to Watch Program
April 2022: NeuBase Therapeutics

  THE COMPANY Drugging the Genome The spark behind NeuBase’s founding, and how the company is drugging the genome with precision genetic medicine.     THE TECHNOLOGY Advancing a New Class of Medicines Founder and CEO Dietrich Stephan and CFO Todd Branning talk about the company’s precision genetic medicine technology and pipeline.       […]

Read More

Drugging the Genome

Company to Watch – NeuBase Therapeutics In the first of four features on NeuBase Therapeutics, Big4Bio spoke with Founder and CEO Dietrich Stephan and CFO Todd Branning about the spark behind founding of the company, and how it is drugging the genome with precision genetic medicine. The second feature will provide an in-depth focus on […]

Read More

Modelling Biology: A Q&A with Cellarity’s CSO Laurens Kruidenier

Company to Watch – Cellarity In the final article in the Company to Watch series on Cellarity, Big4Bio editor Marie Daghlian spoke with Chief Scientific Officer Laurens Kruidenier about what impressed him about the company, what he sees as the strength of the Cellarity platform and how it works, and why we should keep our […]

Read More

Podcast: Transforming Drug Discovery by Focusing on Cell Behavior

Companies to Watch – Cellarity The Big4Bio Podcast · Transforming Drug Discovery by Focusing on Cell Behavior   Fabrice Chouraqui, CEO of Cellarity, speaks about the company’s approach to drug discovery, the technology it is harnessing, and why focusing on cells rather than molecular targets are a better way to discover drugs.     This […]

Read More

A Platform to Uncover Biological Complexity to Target Virtually Any Disease

Company to Watch – Cellarity In the second of four features on Cellarity, Big4Bio spoke with CEO Fabrice Chouraqui about the company’s unique platform, initial pipeline, and plans moving forward. by Marie Daghlian Cellarity aims to discover medicines that can resolve human disease, potentially any disease. To do this it has developed a cell-centric platform […]

Read More

The Big4Bio Company to Watch Program
March 2022: Cellarity

  THE COMPANY A Cell Centric Drug Discovery Platform to Transform Therapeutic Development How Cellarity is uncovering the complexity of human biology and changing the paradigm of classic drug discovery to bring new treatments to patients.   THE TECHNOLOGY, PART 1 A Platform to Uncover Biological Complexity to Target Virtually Any Disease More about the […]

Read More

Priming to Launch “Oligos as a Service”

In the final feature on Molecular Assemblies, Big4Bio spoke with Stephen Bates, vice president of sales and marketing, about the year ahead for the company as it prepares to commercialize its synthetic DNAs. Companies to Watch – Molecular Assemblies by Marie Daghlian Stephen Bates has come full circle in a long career in sales and […]

Read More

Podcast: The Write Stuff — Reinventing the Synthesis of DNA With Enzymes

Companies to Watch – Molecular Assemblies The Big4Bio Podcast · The Write Stuff: Reinventing the Synthesis of DNA with Enzymes Molecular Assemblies’ President and CEO Mike Kamdar and Co-Founder and Chief Scientific Officer Bill Efcavitch talk more about the company’s enzymatic synthesis of DNA and its plans for commercialization.   NEXT WEEK: Q&A with Molecular […]

Read More

Moving Synthetic Biology Into the 21st Century

In the second of four features on Molecular Assemblies, based on a conversation with CEO and President Mike Kamdar and Co-founder and Chief Scientific Officer Bill Efcavitch, Big4Bio takes a deeper look at the company’s enzymatic DNA synthesis technology, why it is needed, and the markets it serves. Companies to Watch – Molecular Assemblies by […]

Read More

Changing the Paradigm for Writing DNA

In the first of four features on Molecular Assemblies, Big4Bio spoke with CEO and President Mike Kamdar and Co-founder and Chief Scientific Officer Bill Efcavitch about how the company got started, their technology for synthesizing DNA and why it is better than current methods, and their plans moving forward. The second feature will provide an […]

Read More

The Big4Bio Company to Watch Program
September 2021: Molecular Assemblies

THE COMPANY/THE MISSION Changing the Paradigm for Writing DNA Molecular Assemblies’ leaders detail how the company got started, the company’s technology for synthesizing DNA, and why that technology is better than current methods.     THE TECHNOLOGY, PART 1 Moving Synthetic Biology into the 21st Century A deeper look at the company’s enzymatic DNA synthesis […]

Read More

Q&A With Meissa Vaccines’ Board Chairperson, Kenneth J. Kelley

In the final feature of Big4Bio’s Company to Watch program for July, we asked Meissa Vaccines’ Board Chairperson Kenneth J. Kelley about his predictions for Meissa and the importance of the company’s efforts. Briefly, tell me how you came to chair Meissa Vaccines’ Board of Directors. Marty Moore reached out to me first for advice […]

Read More